Cytokinetics bags FDA breakthrough therapy status for aficamten in oHCM

Cytokinetics has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). ... Read More